EGFR and non-small cell lung carcinoma: In the phase III FLEX trial where cetuximab with cisplatin/vinorelbine was compared with ciplatin/vinorelbine alone in 1,125 patients with EGFR-detectable advanced NSCLC, a statistically significant improvement in overall survival for the cetuximab group was reported (11.3 months vs. 10.1 months HR 0.871; 95% CI, 0.762–0.996; P = 0.0441).